News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Ionis Pharma (IONS) Release: Enrollment In Phase I/IIa Study Of IONIS-HTT Rx In Patients With Huntington's Disease Completed And Open-Label Extension Study To Open In 2H 2017 6/22/2017
Hutchison China MediTech (Chi-Med) Initiates A Phase I/II Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In China 6/22/2017
BioPharmX To Present Phase IIb Clinical Trial Acne Data At Alabama Dermatology Society Summer Symposium 6/22/2017
Opko Health (OPK) Announces KDIGO Clinical Practice Guideline Update On CKD-MBD 6/22/2017
Why This Small Biotech With A Single Drug In Human Trials Might Be A Big Winner 6/22/2017
Amgen (AMGN) Goes on the Defensive When Critics Call Its Pipeline a Dud 6/22/2017
RXi Pharma (RXII) Announces Completion Of Enrollment Of Phase I/II Clinical Trial With RXI-109 For Retinal Scarring 6/21/2017
InDex Pharmaceuticals AB Enrolls First Patient In The Phase IIb Study CONDUCT With Cobitolimod 6/21/2017
Vanda (VNDA): Several Catalysts Coming Up 6/21/2017
Tolero Pharmaceuticals To Expand Enrollment Of Phase II Study Of Alvocidib In MCL-1-Dependent AML Into Europe 6/21/2017
Epizyme (EPZM) Announces Tazemetostat Granted Orphan Drug Designation For The Treatment Of Soft Tissue Sarcoma 6/21/2017
Kadimastem Received Approval From The Hadassah Hospital IRB (Helsinki Committee) For Conducting A Clinical Trial In ALS Patients 6/21/2017
ErgoMed Release: PeproStat Phase IIb Study Passes Recruitment Mid-Point Ahead Of Schedule 6/21/2017
OncoArendi Therapeutics SA Announces Selection Of Its Second Clinical Development Candidate: OATD-02 For The Treatment Of Multiple Cancers 6/21/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
Enzychem Lifesciences, Corp Announces Initiation Of Global Phase II Trial Of EC-18 In Patients With Chemotherapy Induced Neutropenia(CIN) 6/20/2017
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Announce Independent Radiology Committee Review Confirms Results From Phase II CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 6/20/2017
Neurotech Announces Positive Phase II Results In NT-501 (CNTF) For Macular Telangiectasia 6/20/2017
ARCA biopharma Announces Database Lock For GENETIC-AF Phase IIB Interim Efficacy Analysis – DSMB Recommendation Anticipated In August 2017 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
Neovacs Announces The Completion Of Patient Enrollment In Phase IIb Clinical Study Of IFNalpha Kinoid In Lupus 6/20/2017
Immunicum Announces Publication In Journal For Immunotherapy Of Cancer Of Results Overview From Ilixadencel's First Clinical Study In Metastatic Renal Cell Carcinoma 6/20/2017
New Data Reveals This New York Biotech's Pipeline Could be a Game Changer 6/19/2017
While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines 6/19/2017
GeNeuro Announces First Patient Treated In Phase IIa Study With Gnbac1 In Type 1 Diabetes 6/19/2017
Celgene (CELG) Release: Updated Data From Phase IIb MAGNIFY Study Of REVLIMID (Lenalidomide) And Rituximab Combination (R2) Show Clinical Activity And Responses In Relapsed/Refractory Follicular And Marginal Zone Lymphoma 6/19/2017
Soligenix (SNGX) Release: Complete Efficacy And Long-Term Follow-Up Safety Results From SGX942 Phase II Oral Mucositis Clinical Trial To Be Presented At The 2017 Multinational Association For Supportive Care In Cancer Conference 6/19/2017
Aldeyra (ALDX) To Present Novel Data On The Anti-Inflammatory Mechanism And Activity Of ADX-102 At The World Congress On Inflammation 2017 Annual Meeting 6/19/2017
Merrimack (MACK) Announces Completion Of Enrollment In Phase II CARRIE Study Of MM-141; Data Expected In First Half Of 2018 6/19/2017
Boston Therapeutics Reports Data From The POC Asia Trial At The American Diabetes Association’s 77th Scientific Sessions 6/19/2017
Axovant (AXON) Release: FDA Grants Fast Track Designation To Axovant's Nelotanserin For Visual Hallucinations In Dementia With Lewy Bodies 6/19/2017
Genexine Co. Ltd. Receives Approval To Initiate Phase Ib/II Trial Of GX-188E, HPV Therapeutic DNA Vaccine, In Combination With KEYTRUDA (Pembrolizumab), For The Treatment Of HPV-Induced Cervical Cancer 6/19/2017
BioTime (BTX) Expands & Advances Ophthalmology Portfolio 6/19/2017
Exelixis (EXEL) Announces Independent Radiology Committee Review Confirms Results From CABOSUN, The Phase II Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 6/19/2017
Ammonett Pharma Granted Orphan Drug Designation From The U.S. FDA For Ibutamoren Mesylate (MK-0677) For Treatment Of Growth Hormone Deficiency 6/19/2017
Zealand Pharma  (ZEAL.CO) Release: Glepaglutide Meets Primary Endpoint In Phase II Trial In Patients With Short Bowel Syndrome 6/19/2017
VBL Therapeutics (VBLX) Provides Update On Long-Term Survival In Phase II Trials Of Patients With Multiple Tumor Types 6/19/2017
Aurinia (AUPH) Release: Voclosporin Remission Data From The Phase IIb AURA-LV Study Highlighted At EULAR 2017 6/16/2017
Why Drug Giants Like Merck & Co. (MRK) and AstraZeneca PLC (AZN) Scientists are Looking in the Toilet for New Cancer Treatments 6/16/2017
Epizyme (EPZM) Falls as Investors Take in Disappointing Phase II Data 6/16/2017
Xencor Presents Interim Data From An Ongoing, Open-Label, Phase II Study of XmAb5871 In Igg4-Related Disease At EULAR 2017 6/16/2017
DelMar Pharma Presents Poster Of Clinical Research With VAL-083 In Patients With Chemo-Resistant Glioblastoma ("GBM") At SNO's Pediatric Neuro-Oncology Basic And Translational Research Conference 6/16/2017
MediWound (MDWD) Release: IIndependent Study In Germany Shows NexoBrid Reduces Average Burn Treatment Costs By Nearly 30% Versus Standard Of Care 6/16/2017
BioMarin (BMRN) Announces Acceptance Of Late Breaking Abstract At The International Society On Thrombosis And Haemostasis 2017 Congress 6/16/2017
Bristol-Myers Squibb (BMY) Release: Extended Follow-Up Data Evaluating Opdivo (Nivolumab) Shows Durable Response In Adult Patients With Relapsed Or Progressed Classical Hodgkin Lymphoma 6/16/2017
Mallinckrodt (MNK) Enrolls First Patient In Phase IIB Trial Of H.P. Acthar Gel (Repository Corticotropin Injection) For Amyotrophic Lateral Sclerosis (ALS) 6/15/2017
Seattle Genetics (SGEN) And Bristol-Myers Squibb (BMY) Highlight Interim Phase I/II Data Evaluating Combination Of ADCETRIS (Brentuximab Vedotin) And Opdivo (Nivolumab) In Relapsed Hodgkin Lymphoma At The International Conference On Malignant Lymphoma 6/15/2017
Portola (PTLA) Presents Interim Phase IIa Safety And Efficacy Data For Cerdulatinib At The International Congress Of Malignant Lymphoma 6/15/2017
Debiopharm Announces Completion Of Enrollment In Phase I/II Clinical Trial With Debio 1143 In SCCHN 6/15/2017
Galera Completes Enrollment In Phase IIb Clinical Trial With Lead Compound GC4419 For Treatment Of Oral Mucositis 6/15/2017
Revance (RVNC) Release: Positive BELMONT Phase II Trial Results Published In Dermatologic Surgery 6/15/2017
Selecta (SELB) Reports Data From Ongoing Phase II Trial Of Lead Candidate, SEL-212, In Development For Chronic Severe Gout 6/15/2017
Biotron Limited (BIT:AU) Release: Update On Progress Of Bit225 Phase 2 Hiv-1 Clinical Trial 6/15/2017
Tonix Pharma (TNXP) Participated In The "Pathophysiology Of Posttraumatic Stress Disorder: Rethinking Drug Targets” Summit Sponsored By U.S. Department Of Defense 6/15/2017
Oxford BioMedica PLC (OXB.L) Notes Findings On CTL019 From Phase II JULIET Study Presented At The 14th Meeting Of International Conference On Malignant Lymphoma (ICML) 6/15/2017
Achelios Therapeutics Concludes Successful Type C Meeting With FDA Regarding Its Lead Product, TOPOFEN, For Prevention And Treatment Of Migraine 6/14/2017
Modra Pharma Announces Start Of Phase II Study For Its Lead Oral Chemotherapy In Patients With Metastatic Prostate Cancer 6/14/2017
Epizyme (EPZM) Reports Positive Interim Data From Phase II Trial For Tazemetostat In Relapsed Or Refractory Follicular Lymphoma And DLBCL Patient 6/14/2017
Nordic Nanovector Release: Single Dose Betalutin Continues To Show Promising Efficacy And Safety In Recurrent Indolent NHL Patients 6/14/2017
GenSight Reports Long-Term Positive Safety And Visual Acuity Results At Week 96 In Phase I/II Study Of GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 6/14/2017
Centrexion Announces New 6-Month Data Demonstrating Significant And Durable Pain Relief With CNTX-4975 For Treatment Of Moderate To Severe Knee Osteoarthritis Pain 6/14/2017
AIVITA Comments On Positive Findings From Asterias Biotherapeutics' SCiStar Trial For Spinal Cord Injury 6/14/2017
Aldeyra (ALDX) Schedules Conference Call And Webcast To Announce Results From Allergic Conjunctivitis Phase IIb Clinical Trial 6/14/2017
Celgene (CELG) Release: Phase IIa Safety And Efficacy Data Support Further Development Of Oral CC-220 In Patients With Lupus 6/14/2017
Janssen Pharmaceutical Release: Pimodivir Alone Or In Combination With Oseltamivir Demonstrated A Significant Reduction In Viral Load In Adults With Influenza A 6/14/2017
Aldeyra (ALDX) Plummets As Eye Drug Misses Primary Endpoint In Phase IIb Test 6/14/2017
SoCal's Regulus (RGLS) Sinks After AstraZeneca PLC (AZN) Bails on Lead NASH Drug 6/13/2017
SAGE Therapeutics (SAGE) Announces The Lancet Publishes Positive Phase II Brexanolone (SAGE-547) Clinical Data In Severe Postpartum Depression 6/13/2017
Patients With Complete Paralysis Show Additional Recovery Of Arm, Hand And Finger Function At 9-Months After Treatment With Asterias Biotherapeutics' AST-OPC1 6/13/2017
Galectin (GALT) Announces Important Milestones Towards Completion Of NASH CX Trial 6/13/2017
Acceleron Pharma Ditches Dalantercept After Failure Of Phase II Kidney Cancer Study 6/13/2017
Tarix Orphan Granted Orphan Drug Status By The EMA For TXA127 As Potential Treatment For Epidermolysis Bullosa (EB) 6/12/2017
Eiger Biopharma Reports Additional Positive Phase II Results From Multiple-Ascending Dose Study Of Exendin 9-39 In Post-Bariatric Hypoglycemia Patients At American Diabetes Association Meeting In San Diego 6/12/2017
GTx, Inc. (GTXI) Announces Positive Preliminary Results From Ongoing Phase II Proof-Of-Concept Clinical Trial In Women With Stress Urinary Incontinence 6/12/2017
ProMetic Life Sci (PFSCF.PK) Release: New Data Presented By Prometic At American Diabetes Association's Scientific Sessions Validates PBI-4050's Positive Impact On Kidneys In Patients With Diabetes And Metabolic Syndrome 6/12/2017
vTv Therapeutics (VTVT) Presents Data Highlighting Further Potential Of TTP273 At American Diabetes Association 77th Scientific Sessions 6/12/2017
Zosano (ZSAN) Presents Additional Data From ZOTRIP Study At American Headache Society, Demonstrating Positive Results For Pain Freedom And Sustained Pain Freedom 6/12/2017
Probiodrug AG Announces Encouraging Results Of The Phase IIa SAPHIR Study 6/12/2017
Mateon Therapeutics (MATN) Provides Update On Its Clinical Trial Programs And Milestones 6/12/2017
Intercept Pharma (ICPT) Announces New Data Analysis From FLINT Trial Of OCA In NASH Patients With Type 2 Diabetes 6/12/2017
Sanofi (SNY)'s Rumored Buyout Target Flexion (FLXN) Shows Off Mid-Stage Osteoarthritis Data 6/12/2017
Amgen (AMGN) Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society 6/9/2017
PharmaCyte (PMCB) Updates Shareholders On ASCO Presentation To Oncologists 6/9/2017
KemPharm (KMPH) To Present Clinical Data For KP511, An Opioid Prodrug Candidate, At The International Conference On Opioids 6/9/2017
How This Small Washington Biotech Stands To Outperform Rivals Amgen (AMGN), Eli Lilly (LLY) And Teva (TEVA) In Migraine Drugs 6/9/2017
Zytoprotec GmbH's Novel Dialysis Product Meets Both Endpoints In Phase II Study 6/9/2017
Tiny Bay Area Biotech Wants to Rattle the Billion-Dollar Injectable Drug Markets With a Single Pill 6/8/2017
Bristol-Myers Squibb (BMY) Loses $4.3 Billion in Market Value After ASCO Update 6/8/2017
Loxo Oncology (LOXO) Seeks FDA Approval After Breakthrough Drug Larotrectinib Helped Almost Everyone Who Took It 6/8/2017
Zynerba (ZYNE) Achieves Target Enrollment In Exploratory Phase II Trial Of ZYN002 In Fragile X Syndrome 6/8/2017
AGTC (AGTC) Release: Data Published In Molecular Therapy Demonstrate Five-Year Response Following A Single Dose Of An Investigational Gene-Based Therapy For Alpha-1 Antitrypsin (AAT) Deficiency 6/8/2017
2X Oncology Obtains Investigational New Drug Application For 2X-111 Glutathione Enhanced PEGylated Liposomal Doxorubicin 6/8/2017
Sophiris Bio (SPHS) Announces That The First Patient Has Been Dosed In Phase IIb Study Of Topsalysin In Patients With Clinically Significant Localized Prostate Cancer 6/8/2017
Nordic Nanovector Release: Accepted Abstract By ICML With Updated Results From Phase I/II Trial Of Betalutin In NHL Is Now Available On-Line 6/8/2017
Promius Pharma, LLC Announces Positive Results For Phase II Study Of DFN-02, A Novel Intranasal Formulation Of Sumatriptan 6/8/2017
AVEO Oncology (AVEO) Announces Phase I/II Tinivo Trial Of Tivozanib And Opdivo (Nivolumab) In RCC Advances To Phase II 6/8/2017
NovoCure Release: First Patient Enrolled In RTOG Trial Of Optune Together With Bevacizumab For Patients With Bevacizumab-Refractory Recurrent Glioblastoma 6/8/2017
FDA Calls Y-mAbs, Memorial Sloan-Kettering Cancer Center's Pediatric Cancer Drug a Breakthrough 6/8/2017
CytRx (CYTR) Announces Update On The Regulatory Pathway For Aldoxorubicin In Soft Tissue Sarcomas 6/8/2017
Novartis AG (NVS) Finally Reveals Long-Awaited JULIET CAR-T Data 6/7/2017
Novavax (NVAX) RSV F Vaccine Phase II Clinical Trial Data In Women Of Child Bearing Age Published In Vaccine 6/7/2017
Rebiotix Data Presented At ASM Microbe 2017 Show RBX2660 Treated Patients' Clinical Success Correlates With Improved Microbiome Diversity 6/7/2017
AVANIR (AVNR) Initiates Phase II Study To Evaluate AVP-786 For Treatment Of Neurobehavioral Disinhibition Associated With Traumatic Brain Injury 6/7/2017
Sangamo (SGMO) And Pfizer (PFE) Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The EMA 6/7/2017
ArQule (ARQL) Announces First Patient Dosed In Company Sponsored Phase I/II Trial Of AKT Inhibitor, ARQ 092, For Rare Overgrowth Diseases 6/7/2017
Protalix (PLX) Announces Phase II Clinical Trial Results For Alidornase Alfa In Cystic Fibrosis Presented At The 40th European Cystic Fibrosis Society Conference 6/7/2017
Kamada Ltd. (KMDA) Provides Update On Clinical Program For Alpha-1 Antitrypsin IV For Treatment Of Graft-Versus-Host Disease 6/7/2017
Soin Neuroscience Files An Orphan Drug Application To Treat Systemic Sclerosis 6/7/2017
LLCT Release: Living Cell Technologies' NTCELL Continues To Halt Progression Of Parkinson's Disease 6/6/2017
Revance (RVNC) Reports Additional Positive Week 24 Efficacy Results From RT002 Injectable Phase II Cervical Dystonia Trial 6/6/2017
ChemoCentryx (CCXI) Release: Oral Presentations At ERA-EDTA Congress Highlight Fourth Potential Indication For Avacopan And Potential For CCR2 Inhibition In Focal Segmental Glomerulosclerosis (FSGS) 6/6/2017
Astellas (ALPMY) Release: Exploratory Analysis Of The Phase I/II CHRYSALIS Study Of Gilteritinib Demonstrates First Molecular Response To FLT3 Inhibitor In Acute Myeloid Leukemia 6/6/2017
Boston Biomedical Presents Data For Investigational Stemness Inhibitor Amcasertib At ASCO 2017 6/6/2017
Eiger Biopharma Completes Enrollment In Phase II Multiple-Ascending Dose Study Of Exendin 9-39 In Post-Bariatric Hypoglycemia Patients 6/6/2017
Poxel (POXEL.PA) Announces Additional Positive Results For Imeglimin Phase IIb Study In Japan For The Treatment Of Type 2 Diabetes 6/6/2017
NIH And Themis Bioscience Announce The Initiation Of A Clinical Trial Of A Chikungunya Vaccine 6/6/2017
MorphoSys AG Presents First Safety And Efficacy Data Of MOR208 In Combination With Lenalidomide From A Phase II Study In DLBCL 6/6/2017
Questions Rise As Incyte (INCY) Omits Response Rate Data From Several Patients Enrolled In IDO Lung Cancer Study 6/5/2017
Aurinia (AUPH) Presents Additional Data From Phase IIb AURA-LV Study, Demonstrating Stable Renal Function And Blood Pressure Without Electrolyte Complications Through 48 Weeks 6/5/2017
Matinas BioPharma Announces Interim Data From NIH-Conducted Phase IIa Clinical Study Of Orally-Administered MAT2203 For The Treatment Of Chronic Refractory Mucocutaneous Candidiasis 6/5/2017
Rexahn Pharmaceuticals, Inc. (RNN) Presents Preliminary Efficacy Data From The Ongoing Phase IIa Clinical Trial Of RX-3117 In Metastatic Bladder Cancer At The ASCO 2017 Annual Meeting 6/5/2017
Avivagen Provides Business Updates 6/5/2017
SCYNEXIS, Inc. (SCYX) Release: Eight Presentations At ASM Microbe 2017 Further Highlight The Strong Antifungal Effect And Promising Safety Profile Of Lead Anti-Infective Candidate SCY-078 6/5/2017
Novartis AG (NVS) Landmark Study Of Tafinlar + Mekinist Demonstrates Durable Survival Benefit At Five Years In Patients With BRAF Mutation-Positive Metastatic Melanoma 6/5/2017
Medical Prognosis Institute - The Efficacy Of Chemotherapy With Epirubicin, One The Of Most Used Drugs In Breast Cancer Can Now Be Predicted By DRP - Poster Published At ASCO 6/5/2017
Prima Biomed (PRR.AX) Release: LAG-3Ig (IMP321) Demonstrates Positive Safety And Efficacy Qualities In Breast Cancer Clinical Trial 6/5/2017
Eisai Company (ESALY.PK) To Present Results Of Phase Ib/II Study Of Anticancer Agent Lenvima (Lenvatinib) In Combination With Anti-PD-1 Antibody Pembrolizumab 6/5/2017
MorphoSys AG Presents Updated Clinical Data For Anti-CD38 Antibody MOR202 In Multiple Myeloma At ASCO 2017 6/5/2017
Further Study Of Combination Of Eisai Inc. (ESALF.PK)'s Lenvatinib And Merck & Co. (MRK)'s Pembrolizumab In Previously Treated Patients With Metastatic Endometrial Cancer Supported By Interim Analysis Of Ongoing Phase Ib/II Trial 6/5/2017
Amgen (AMGN) Presents New Phase II Data On IMLYGIC (Talimogene Laherparepvec) Investigational Combination At ASCO 2017 6/5/2017
Halozyme (HALO) Phase II Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO 6/5/2017
Incyte (INCY) Release: Clinical Trial Data For Combination Of Epacadostat And Opdivo (Nivolumab) Demonstrate Durable Clinical Responses In Patients With Melanoma And Head And Neck Cancer 6/5/2017
Bristol-Myers Squibb (BMY) Release: Encouraging Disease Control Rates Observed With Nivolumab Alone Or In Combination With Ipilimumab In Refractory Or Relapsing Malignant Pleural Mesothelioma Patients: Results From IFCT-1501 MAPS-2 Trial 6/5/2017
Boehringer Ingelheim Release: Encouraging Phase II Survival Data For Oral Nintedanib In Malignant Pleural Mesothelioma Presented At ASCO 2017 6/5/2017
Boston Biomedical Presents Data Suggesting Anti-Cancer Activity Of Investigational Stemness Inhibitor Napabucasin In Seven Tumor Types At ASCO 2017 6/5/2017
Bristol-Myers Squibb (BMY) Release: Early, Durable Responses Seen With Sprycel (Dasatinib) In First- And Second-Line Treatment Of Pediatric Patients With Chronic Myeloid Leukemia In Chronic Phase (CP-CML) 6/5/2017
New Data From Phase II I-SPY 2 TRIAL Shows Improved Outcomes With Combination Of Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) Plus Standard Neoadjuvant Therapy In Patients With High-Risk Breast Cancer 6/5/2017
GlycoMimetics (GLYC) Presents Updated Data From Ongoing Phase I/II Clinical Trial Of GMI-1271 In Patients With Acute Myeloid Leukemia At ASCO 2017 Annual Meeting 6/5/2017
Novoteris, LLC Receives FDA And Health Canada Clearance To Start A Phase II Clinical Trial Of Its Thiolanox Nitric Oxide For The Treatment Of Cystic Fibrosis 6/5/2017
Helsinn And MEI Pharma (MEIP) Report Correlation Between Mutations In DNA Methylation Pathway And Clinical Response In Phase II Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia 6/5/2017
Viamet Presents Phase IIb Results Demonstrating Unprecedented Efficacy Of Oral VT-1161 In The Treatment Of Recurrent Vulvovaginal Candidiasis 6/5/2017
New Monotherapy Data For Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) In Heavily Pre-Treated Patients With Advanced Gastric Cancer To Be Presented At 2017 ASCO Annual Meeting 6/5/2017
Aridis Pharma Presents Positive Phase IIa Safety And Efficacy Data Of Salvecin (AR-301) In Patients With Severe Pneumonia Caused By Staphylococcus Aureus During The 2017 ASM Microbe Congress 6/5/2017
Positive Phase IIb Trial Of Pharmalink AB's Nefecon In Primary IgA Nephropathy Presented At Leading Kidney Disease Conference 6/5/2017
Bristol-Myers Squibb (BMY) Release: First Presentation Of Efficacy Data From Checkmate -204 Evaluating The Combination Of Opdivo (Nivolumab) And Yervoy (Ipilimumab)Demonstrates Anti-Tumor Activity In Advanced Melanoma Patients With Brain Metastases 6/5/2017
NewLink Genetics (NLNK) Release: Results From Clinical Trial Of Indoximod Plus Chemotherapy For Patients With Metastatic Breast Cancer 6/5/2017
Pfizer (PFE) Presents Final Phase II Data On Investigational PARP Inhibitor Talazoparib In Patients With Germline BRCA-Positive Advanced Breast Cancer 6/5/2017
NewLink Genetics (NLNK)’ Indoximod + PROVENGE Results In Statistically Significant Improvement In Radiographic Progression-Free Survival (rPFS) For Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) In Phase II Trial 6/5/2017
Puma Biotech (PBYI) Announces Positive PB272 Phase II Data From TBCRC 022 Trial In Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases At The 2017 ASCO Annual Meeting 6/5/2017
NeuroDerm (NDRM) Presents ND0612H Phase II Trial Results In Late-Breaking Poster Session At The 21st International Congress Of Parkinson’s Disease And Movement Disorders 6/5/2017
Celldex (CLDX) Presents Promising Overall Survival Data From Phase II Study Of Single-Agent Glembatumumab Vedotin In Patients With Checkpoint-Refractory Metastatic Melanoma 6/5/2017
Incyte (INCY) Release: Combination Of Epacadostat Plus Keytruda (Pembrolizumab) Demonstrates Activity In Clinical Trial Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) 6/5/2017
ArQule (ARQL) Presents Phase 1/2 Clinical Data With ARQ 087 In Intrahepatic Cholangiocarcinoma At The 2017 ASCO Annual Meeting 6/5/2017
Bristol-Myers Squibb (BMY) Release: Opdivo (Nivolumab) In Combination With Yervoy (Ipilimumab) Demonstrated Promising Activity In Previously Treated Patients With Dmmr Or MSI-H Metastatic Colorectal Cancer In Phase II Checkmate -142 Study 6/5/2017
HalioDx Highlights Use Of Immunosign To Define CAR T-Cell Therapy Signature In Tumor At ASCO 2017 6/5/2017
New Data Show Durability Of Response For Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) In Advanced Microsatellite Instability-High (MSI-H) Or Mismatch Repair Deficient (Dmmr) Solid Tumors, Regardless Of Tumor Type 6/5/2017
Longer Term Follow-Up Data With Merck & Co. (MRK)’S KEYTRUDA (Pembrolizumab) In Combination With Pemetrexed And Carboplatin In First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) To Be Presented At 2017 ASCO Annual Meeting 6/5/2017
Onconova (ONTX) Announces Positive Phase II Data In Rigosertib Treated Patients With Second-Line Myelodysplastic Syndromes At The ASCO Annual Meeting 6/5/2017
Bristol-Myers Squibb (BMY) Release: Anti-LAG-3 (Bms-986016) In Combination With Opdivo (Nivolumab) Showed Activity In Patients With Melanoma Who Were Relapsed Or Refractory To Anti-PD-1/PD-L1 Therapy 6/5/2017
Viamet Data For VT-1161 And VT-1598 To Be Presented At American Society of Microbiology’s ASM Microbe 2017 Conference 6/5/2017
Novartis AG (NVS) Lays Out R&D Game Plan at Meet and Greet With 30 Execs in Boston 6/2/2017
Windtree Therapeutics (WINT) Announces Successful Completion Of Enrollment In AEROSURF Phase IIb Clinical Trial For The Treatment Of Respiratory Distress Syndrome (RDS) In Premature Infants 6/2/2017
Bristol-Myers Squibb (BMY) Release: Opdivo (Nivolumab) Data In Patients With Advanced Cervical, Vaginal And Vulvar Cancers From Phase I/II Checkmate -358 Presented At ASCO 6/2/2017
Reata Pharmaceuticals, Inc. Announces Positive Data From Part One Of Moxie Trial Of Omaveloxolone For Friedreich’s Ataxia 6/2/2017
Flex’s Phase II Trial With FLX-787 In Charcot-Marie-Tooth Endorsed By The Inherited Neuropathies Consortium 6/2/2017
A Look at Gilead (GILD)'s Possible New Drug Strategy 6/1/2017
AMAG (AMAG) Announces First Patient Enrolled In Phase IIb/IIIa Digoxin Immune Fab Study Conducted By Velo Bio 6/1/2017
Vaxon Biotech SA Announces Results Of Its Phase IIb Lung Cancer Trial Of Vx-001, A Therapeutic Vaccine Based On Optimized Cryptic Peptides 6/1/2017
BioPharmX Advances BPX-01 2% Upon Achieving Statistical Significance For Primary Endpoint 6/1/2017
CytoDyn (CYDY) To Present An Update On Its PRO 140 Pivotal Phase IIb/III Study In Treatment-Experienced HIV-1 Patients At ASM Microbe 2017 6/1/2017
Ocera Therapeutics (OCRX) Initiates Phase IIa Study With Oral OCR-002 In Patients With Cirrhosis 6/1/2017
Origin, Inc. Announces First 50 Patients Randomized, And Full Site Activation In Phase IIb Dose-Ranging Study For Diabetic Foot Ulcers 6/1/2017
BioPharm Executive: Here's What to Look For at ASCO 5/31/2017
Asana Biosciences Initiates Phase II Evaluation Of ASN002, A Novel Syk/Jak Inhibitor, In NHL, CLL And MF 5/31/2017
Capricor Announces Upcoming Events In Duchenne Muscular Dystrophy Program 5/31/2017
Ralexar Therapeutics Initiates Phase IIb Study Of ALX-101 In Patients With Atopic Dermatitis 5/31/2017
NLS Pharma Touts Positive Phase II ADHD Data 5/31/2017
Amicus (FOLD) Receives Rare Pediatric Disease Designation For SD-101 For Patients With Epidermolysis Bullosa 5/31/2017
Tonix Pharma (TNXP) Presented Retrospective Analyses Of Treatment Response And Remission To TNX-102 SL In A Phase II Military-Related PTSD Study 5/31/2017
Intensity Therapeutics, Inc. Successfully Administers INT230-6 To First Patient In A Phase I/II Trial 5/30/2017
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy 5/30/2017
NLS Pharma Announces New Information In Support Of The Mechanism Of Action Of Its Lead Compound NLS-1 Mazindol CR 5/30/2017
HedgePath Pharmaceuticals Announces Granting Of Type-C Meeting Request By FDA And Provides Positive Clinical Trial Update 5/30/2017
Abeona Therapeutics Receives Rare Pediatric Disease Designation For EB-101 Gene Therapy Product For Patients With Epidermolysis Bullosa 5/30/2017
How Much Juno (JUNO) Spent on Its Failed CAR-T Drug 5/30/2017
5 Big Pharmas Facing Catalysts in 2017 5/26/2017
Biocryst (BCRX) Stock Caught Fire After Reporting Positive Phase II HAE Data 5/26/2017
Regeneron (REGN) Announces ANGPTL3/Evinacumab Publication In The New England Journal of Medicine And Positive Phase ll Data In People With HoFH 5/25/2017
TrovaGene (TROV) Release: Phase l Safety Study Supports Planned Development Of PCM-075 In AML 5/25/2017
Centrexion To Present Data On CNTX-4975 For The Treatment Of Chronic Pain Associated With Knee Osteoarthritis At European Federation Of National Associations Of Orthopaedics And Traumatology’s 2017 Annual Congress 5/25/2017
Akcea Therapeutics Announces Publication In The New England Journal of Medicine Of Data With AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects 5/25/2017
Abeona Therapeutics Receives FDA Orphan Drug Designation For EB-101 Gene Therapy Product For Patients With Epidermolysis Bullosa 5/25/2017
GlycoMimetics (GLYC)' GMI-1271 Receives EU Orphan Drug Designation For Acute Myeloid Leukemia 5/25/2017
X4 Pharma Announces Initiation Of The Phase II Expansion Of Its Phase I/II Study Of X4P-001 In Patients With Advanced Clear Cell Renal Cell Carcinoma 5/25/2017
Akcea Therapeutics Announces Publication In The New England Journal of Medicine Of Data With AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects 5/25/2017
Hepatera: Eligibility To PRIME Scheme Granted To Myrcludex B By The EMA 5/25/2017
Neurocrine (NBIX) Tanks as Tourette Syndrome Drug Flunks Mid-Stage Study 5/24/2017
6 (Plus 2!) Most Notable ASCO Abstracts So Far 5/24/2017
Sophiris Bio (SPHS) Provides Update On Phase llb Study Of Topsalysin In Localized Prostate Cancer 5/24/2017
Myovant (MYOV) Announces Presentation Of Data At The European Congress Of Endocrinology From Phase ll Extension Study Evaluating Relugolix In Women With Endometriosis-Associated Pain 5/24/2017



//-->